scholarly journals Postoperative complicated peripheral cortical cataract after ultrasound cycloplasty: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jihan Luo ◽  
Zhen Liu ◽  
Lin Zhao ◽  
Yi Zhou ◽  
Li Kong ◽  
...  

Abstract Background Ultrasound cycloplasty (UCP) is a non-invasive procedure for glaucoma treatment. Using high-intensity focused ultrasound to work on the ciliary body, the generation of aqueous humor can be reduced and the drainage of aqueous humor through the uveoscleral pathway can be enhanced. Recently, this therapy is gradually gaining clinical recognition. We report a case of a patient with glaucoma who accepted UCP in another hospital, but because of a worsening of a preexistent cataract and an insufficient IOP lowering effect, finally underwent cataract surgery in both eyes in our hospital, during the surgery we observed the unusual opacities probably due to UCP mistreatment. Case presentation Patient was diagnosed as chronic angle closure glaucoma and catacract, accepted UCP on both eyes in another hospital 4 months ago. After the UCP therapy, the pupil was vertical ellipse, the UCP didn’t have a sufficient effect on IOP and forced us to do cataract surgery to lower IOP. During the cataract surgery, some unusual white opacities in the peripheral cortex with clear boundary were found. Inaccurate WtW measurement was the most likely cause of the injury, which resulted in the use of the small-size UCP probe and the downward movement of the UCP probe. Conclusion UCP should not be a first line treatment in a patient with cataract and angle closure glaucoma, cataract extraction is a better choice. The appropriate case selection needs to be more strict and the preoperative indexes measurements need to be more accurate.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17600-e17600
Author(s):  
Alessandro Napoli ◽  
Luca Marchetti ◽  
Enrico Cortesi ◽  
Paolo Marchetti

e17600 Background: With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Our aim was to determine MRgFUS ability to downstage patients with oligometastatic bone disease with single session of non-invasive metastasis-directed therapy. Methods: The study was designed with intention-to-treat metastatic bone lesions. Patients were enrolled if they had accessible bone metastasis and could safely undergo MRgFUS (InSightec, Israel). Baseline measurable characteristics included dynamic contrast enhanced MRI study (DCE; Gd-BOPTA, Bracco; GE 750 3T magnet) with semiquantitative perfusion analysis, PSA level (ng/ml) and choline PET (SUV). Measurable variables were obtained at treatment time, 3 months, 12 months and 24 months follow-up. Results: 18 patients fulfilled the inclusion criteria and safely underwent MRgFUS procedure of metastatic bone ablations. Lesions were located in the pelvis (11), scapula (3) and long bones (4). At baseline all lesions showed a significant DCE perfusion (highly vascular) with mean perfusion reduction of 88% at 3 months follow-up (CI: 100-50; p < 0.001) stable at subsequent follow-up scans. Similarly PSA levels decreased from a mean baseline of 19 (ng/ml) to 7.1, 2.9 and 2.1, at 3-12 and 24 moths respectively. SUV values showed similar trend with reduction from baseline (mean 8.9 to 3.0, 2.3 and 1.7: p < 0.001). In all patients single MRgFUS session was appropriate without any major or minor adverse events reported. Conclusions: MRgFUS is a totally non-invasive procedure that can obtain complete bone ablation in patients with oligometastatic prostate disease. The technique features a radiation-free approach that can be of incremental value in long-survivor subset on oncological patients, significantly reducing risk of toxic effects. Concurrent chemo regimen is not a contraindication.


Sign in / Sign up

Export Citation Format

Share Document